All
Research
Education
Onderzoek
Onderwijs
Business
Oplossingen
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Türkçe
JA - 日本語
PL - Polski
RU - Русский
HE - עִברִית
AR - العربية
Meld u aan
Vincenza Conteduca has not added Biography.
If you are Vincenza Conteduca and would like to personalize this page please email our Author Liaison for assistance.
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.
Oncotarget Dec, 2014 | Pubmed ID: 25504434
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
Oncotarget Jun, 2016 | Pubmed ID: 27191887
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Oncotarget 08, 2016 | Pubmed ID: 27409344
Cell-free DNA as a diagnostic marker for cancer: current insights.
OncoTargets and therapy , 2016 | Pubmed ID: 27822059
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Scientific reports Nov, 2017 | Pubmed ID: 29138500
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Samanta Salvi1,
Vincenza Conteduca1,
Filippo Martignano1,
Giorgia Gurioli1,
Daniele Calistri1,
Valentina Casadio1
1, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Privacy
Gebruiksvoorwaarden
Beleid
Neem contact met ons op.
Aanbevelen aan bibliotheek
JoVE Nieuwsbrieven
JoVE Journal
Methoden Collecties
JoVE Encyclopedia of Experiments
Archiveren
JoVE Core
JoVE Science Education
JoVE Lab Manual
JoVE Quiz
JoVE Playlist
Auteurs
Bibliothecarissen
Toegang
Over JoVE
JoVE Sitemap
Auteursrecht © 2025 MyJoVE Corporation. Alle rechten voorbehouden